Clinical Trials Logo

Muscle Injury clinical trials

View clinical trials related to Muscle Injury.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05946746 Recruiting - Muscle Injury Clinical Trials

The Effects of PeptiStrong and Exercise to Enhance Muscle Strength in Young Subjects

Start date: August 9, 2023
Phase: N/A
Study type: Interventional

A randomised, double-blind, placebo controlled study to evaluate the effect of PeptiStrong supplementation in conjunction with an exercise program to enhance muscle strength and endurance in young male and female subjects.

NCT ID: NCT05746650 Recruiting - Muscle Injury Clinical Trials

Improving Tissue Repair After Injury in the Muscle-tendon Interface Muscle Tissue Injury

GH-MTJ
Start date: February 24, 2023
Phase: N/A
Study type: Interventional

The study is a 2-week human study where 40 patients who are scheduled to undergo reconstructive knee surgery are randomized to administration of GH or placebo following or without neuromuscular electrical stimulation of hamstring muscles.The overall aim is to determine, the role of muscle connective tissue protein synthesis in muscle injury and repair.

NCT ID: NCT05344183 Recruiting - Fatigue Clinical Trials

Immediate and Short-term Effects of Low-level Laser

Start date: September 3, 2022
Phase: N/A
Study type: Interventional

Athletes experience an exhaustive routine of training, associated with the reduced time of rest, facilitates the appearance of muscle fatigue, which increases the risk of muscle injuries, especially during the execution of the jump. Low Level Lasertherapy is a technique that has been increasingly improved due to the physiological effects it provides in the muscle recovery process. However, there is still a lack of studies focused on the use of this technique in functional improvement, especially in jumping sports. Objectives: To evaluate the immediate and short-term effects of low-level laser on the functional performance of lower limbs of jumping athletes and to evaluate the short-term effects of low-level laser on the activation of the gluteus medius and quadriceps muscles. Methods: This is a brief, double-blind, randomized, placebo-controlled clinical trial. Will be recruited 24 handball and volleyball players aged between 18 to 35 years. The primary outcome of our study is functional performance (modified hop test and modified SEBT), and as a secondary outcome (level of electromyographic activity). After the baseline assessments, the athletes will be randomized and allocated into two groups: Intervention Group (IG, n=12) and Control Group (CG, n=12) and submitted to a fatigue protocol, followed by laser therapy or placebo.

NCT ID: NCT05216666 Recruiting - Muscle Weakness Clinical Trials

The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty

HSS
Start date: May 11, 2022
Phase: N/A
Study type: Interventional

Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.

NCT ID: NCT03660969 Recruiting - Muscle Weakness Clinical Trials

Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease

H&M
Start date: January 1, 2018
Phase:
Study type: Observational

Visits to the emergency department (ED) for chest pain are extremely common and require a safe, rapid and efficacious treatment algorithm to exclude a possible AMI. These diagnostic algorithms are partly based on an important laboratory value, which showed growing utility in the diagnostic and prognostic of many cardiovascular diseases in the last years : cardiac troponin. However, some patients with muscle disease often present with unexplained elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in the absence of cardiac disease. The investigators aim at the characterization of the behaviour of this biomarker and its alternative (high-sensitive cardiac Troponin I), which will have important clinical implications on patients management.